Admedus Ltd (ASX:AHZ) has passed a key development milestone for its transcatheter aortic valve replacement (TAVR) device project.
TAVR is where a valve is placed into the heart via a catheter (usually inserted through the leg) to replace the aortic valve, eliminating the need for open-heart surgery.
The US$3.5 billion market is expected to grow to US$7.5 billion by 2024.
Admedus’s TAVR device has advantages over current products
Current TAVR products on the market contain three separate pieces of tissue held together by more than 100 sutures.
In comparison, the Admedus TAVR prototype device is a uni-body 3D moulded aortic valve design.
Durability benchmark of 200 million cycle tests completed
The TAVR device project passed a key developmental milestone by achieving the durability benchmark of 200 million cycle tests.
Wayne Paterson, CEO, said: “Passing the 200 million valve cycle test is a critical step in this pre-clinical stage of development as it confirms the valve meets the required standard of durability - fundamental to the overall viability and progression of the project.
“There’s still a lot of work to be done in the development and testing phases but successfully completing the cycle durability test gives us the green light to continue our investment in this strategically important initiative.
“If successful, the Admedus TAVR will reinvent the way these devices are used and manufactured.”
READ: Admedus enters agreement opening sales channel to 1,500 hospitals
Recently, Admedus entered a purchasing agreement allowing it to promote its flagship ADAPT® tissue products, CardioCel® and VascuCel®, to more than 1,500 hospitals.